Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3,3-Difluoro-Piperidinium SCHEMBL13517 | 0.84 | — | — | |
| 3,3-Difluoro-Piperidinium SCHEMBL16415145 | 0.84 | — | — | |
| 3,3-Difluoro-Piperidinium SCHEMBL28255979 | 0.84 | HSD17B10 (0.32) | HSD17B10 | |
| 3,3-Difluoro-Piperidinium SCHEMBL27771281 | 0.82 | — | — | |
| 3,3-Difluoro-Piperidinium SCHEMBL230371 | 0.82 | — | — | |
| SCHEMBL19320328 | 0.77 | — | — | |
| SCHEMBL16925525 | 0.75 | ALDH1A1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL2572038 | 0.75 | ALDH1A1 (0.33) | — | |
| Azetidine SCHEMBL790284 | 0.74 | — | — | |
| SCHEMBL13941679 | 0.72 | HSD17B10 (0.31) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2022-01-27 | — | — | US | disclosed |
| CN-107849010-B | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-107849010-B | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-11136328-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-10-05 | — | — | US | disclosed |
| US-10584127-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (BM) | 2020-03-10 | — | — | US | disclosed |
| US-10294230-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-05-21 | — | — | US | disclosed |
| CN-107849010-A | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-107849010-A | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2018-03-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294230-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | KDM4E 1521/4885KMT2A 545/4885MAPT 2464/4885 |
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | KDM4E 1487/4885KMT2A 557/4885MAPT 2475/4885 |
| US-11136328-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | KDM4E 1487/4885KMT2A 557/4885MAPT 2475/4885 |
| US-10584127-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | KDM4E 1487/4885KMT2A 557/4885MAPT 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.